¼¼°èÀÇ ´ç´¢º´¼º ½Å°æÀå¾Ö °ü¸® ½ÃÀå
Diabetic Neuropathy Management
»óǰÄÚµå : 1779930
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 382 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,204,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,612,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ´ç´¢º´¼º ½Å°æÀå¾Ö °ü¸® ½ÃÀåÀº 2030³â±îÁö 35¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 27¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ´ç´¢º´¼º ½Å°æÀå¾Ö °ü¸® ½ÃÀåÀº 2024-2030³â¿¡ CAGR 4.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 35¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ½Å°æ ÀÚ±Ø ±â±â´Â CAGR 5.3%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 18¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àü±â ÀÚ±Ø ±â±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 4.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 7¾ï 2,790¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´ç´¢º´¼º ½Å°æÀå¾Ö °ü¸® ½ÃÀåÀº 2024³â¿¡ 7¾ï 2,790¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 8.5%·Î ÃßÀÌÇϸç, 2030³â¿¡´Â 7¾ï 3,150¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.9%¿Í 3.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ´ç´¢º´¼º ½Å°æº´Áõ °ü¸® ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

´ç´¢º´¼º ½Å°æº´Áõ°¡ ÁÖ¿ä °Ç°­¹®Á¦·Î ¶°¿À¸¥ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

´ç´¢º´¼º ½Å°æº´ÁõÀº Àå±â°£ÀÇ °íÇ÷´ç »óÅ·ΠÀÎÇÑ ½É°¢ÇÑ ÇÕº´ÁõÀ¸·Î Àü ¼¼°è ¼ö¹é¸¸ ¸íÀÇ ´ç´¢º´ ȯÀÚ°¡ ¾Î°í ÀÖÀ¸¸ç, ½Å°æ ¼Õ»ó, ¸¸¼º ÅëÁõ, ¿îµ¿ ´É·Â ÀúÇϸ¦ À¯¹ßÇϰí ÀÖ½À´Ï´Ù. ÀÌ ÁúȯÀº ÁÖ·Î ¸»ÃʽŰæ°è¿¡ ¿µÇâÀ» ¹ÌÄ¡¸ç, ¸¶ºñ, ÀÛ¿­°¨, ¹«°¨°¢, ¹«°¨°¢, ±Ù·ÂÀúÇÏ µîÀÇ Áõ»óÀ» À¯¹ßÇÕ´Ï´Ù. ´ç´¢º´ Àα¸ Áõ°¡¿Í ´õºÒ¾î Ç÷´ç Á¶ÀýÀÌ Àß ¾ÈµÇ°í ¾É¾Æ¼­ »ýȰÇÏ´Â »ýȰ½À°üÀÌ ´ç´¢º´¼º ½Å°æº´Áõ Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ Áõ»óÀº ȯÀÚÀÇ »îÀÇ Áú¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡±â ¶§¹®¿¡ È¿°úÀûÀÎ °ü¸® Àü·«ÀÌ ÇʼöÀûÀÔ´Ï´Ù. ÇコÄÉ¾î ¾÷°è¿¡¼­´Â Áõ»óÀ» ¿ÏÈ­Çϰí Áúº´ÀÇ ÁøÇàÀ» ´ÊÃß±â À§ÇÑ ¾à¸®ÇÐÀû Ä¡·á¿Í ºñ¾à¸®ÇÐÀû Ä¡·á ¸ðµÎ¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. Á¶±â Áø´Ü ¹× ¿¹¹æ Á¶Ä¡¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ Á¾ÇÕÀûÀÎ ½Å°æ Àå¾Ö °ü¸® ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ ´õ¿í ³ô¾ÆÁ® ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

´ç´¢º´¼º ½Å°æº´Áõ °ü¸®ÀÇ ÃֽŠġ·á¹ýÀº ¹«¾ùÀΰ¡?

´ç´¢º´¼º ½Å°æº´ÁõÀÇ °ü¸® »óȲÀº ½Å¾à, ½Å°æÁ¶Àý ±â±â, Àç»ýÀÇ·á Á¢±Ù¹ý µî ÷´Ü Ä¡·á¹ýÀÇ µµÀÔÀ¸·Î ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ÇÁ·¹°¡¹ß¸°, µà·Ï¼¼Æ¾°ú °°Àº Ç×°æ·ÃÁ¦ ¹× Ç׿ì¿ïÁ¦´Â ¿©ÀüÈ÷ ¾à¸®ÇÐÀû Ä¡·áÀÇ ÁÖÃàÀ¸·Î ½Å°æº´Áõ¼º ÅëÁõÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ±×·¯³ª À¯ÀüÀÚ Ä¡·á¿Í ½Å°æ Àç»ý Ä¡·áÀÇ ÃâÇöÀº ±Ùº»ÀûÀÎ ½Å°æ ¼Õ»ó¿¡ ´ëóÇÒ ¼ö ÀÖ´Â À¯¸Á ÇØ°áÃ¥À» Á¦°øÇÕ´Ï´Ù. °æÇÇÀû Àü±â½Å°æÀÚ±Ø(TENS)À̳ª ô¼ö ÀÚ±ØÀ» Æ÷ÇÔÇÑ ºñħ½ÀÀû ½Å°æÁ¶Àý¿ä¹ýÀº ÅëÁõ ¿ÏÈ­¸¦ À§ÇÑ ´ëü Ä¡·á¹ýÀ¸·Î °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áٱ⼼Æ÷ Ä¡·á°¡ ½Å°æ±â´ÉÀ» ȸº¹½ÃÄÑ Àå±âÀûÀÎ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀÌ °ËÅäµÇ°í ÀÖ½À´Ï´Ù. ¾à¹° Ä¡·á¿Í ±â±â Ä¡·áÀÇ ²÷ÀÓ¾ø´Â Çõ½ÅÀ¸·Î ´ç´¢º´¼º ½Å°æº´Áõ °ü¸® ½ÃÀåÀº ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

»ýȰ½À°ü °³¼±°ú ´ëü¿ä¹ýÀº ¾î¶»°Ô ½ÃÀåÀ» Çü¼ºÇϰí Àִ°¡?

´ç´¢º´¼º ½Å°æº´ÁõÀÇ °ü¸®¿¡¼­ ÀüÅëÀûÀÎ Ä¡·á ¿Ü¿¡µµ »ýȰ½À°ü °³¼±°ú ´ëü¿ä¹ýÀÌ Á¡Á¡ ´õ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ºñŸ¹Î B12¿Í ¥á-¸®Æ÷»ê º¸ÃæÀ» Áß½ÉÀ¸·Î ÇÑ ¿µ¾ç ÁßÀç´Â ½Å°æ °Ç°­À» Áö¿øÇÏ°í »êÈ­ ½ºÆ®·¹½º¸¦ ÁÙÀ̱â À§ÇØ ±ÇÀåµÇ°í ÀÖ½À´Ï´Ù. ħ¼ú, ÇѾà, ¹°¸®Ä¡·á µî º¸¿Ï¿ä¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÀüÀÎÀû °ü¸® Á¢±Ù¹ýÀ» ¿øÇϴ ȯÀÚµéÀÇ Ä¡·á ¼±ÅñÇÀÌ ³Ð¾îÁö°í ÀÖ½À´Ï´Ù. ½Å°æ ±â´É°ú ¼øÈ¯À» °³¼±Çϵµ·Ï Á¶Á¤µÈ ¿îµ¿ ÇÁ·Î±×·¥µµ ½Å°æ Àå¾Ö °ü¸®¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ÅëÇÕÀÇ·á¿Í ¸ÂÃã Ä¡·á °èȹ¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ´ÙÇÐÁ¦Àû Ä¡·á ¸ðµ¨ °³¹ß¿¡ ¿µÇâÀ» ¹ÌÃÄ È¯ÀÚµéÀÇ Ä¡·á °á°ú¸¦ ´õ¿í Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

´ç´¢º´¼º ½Å°æº´Áõ °ü¸® ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀÎÀº?

´ç´¢º´¼º ½Å°æº´Áõ °ü¸® ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è ´ç´¢º´ Àα¸ Áõ°¡, »õ·Î¿î ¾à¹° ¿ä¹ýÀÇ Ã¤Åà Áõ°¡, ½Å°æÁ¶Àý ±â¼úÀÇ ¹ßÀü µî ¿©·¯ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. Á¶±â Áø´Ü°ú Á¶±â °³ÀÔÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ´õ ¸¹Àº ȯÀÚµéÀÌ Ä¡·á¸¦ ¹Þµµ·Ï À¯µµÇÏ¿© ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÅëÁõ °ü¸® ¼Ö·ç¼Ç, ƯÈ÷ ºñ¿ÀÇÇ¿ÀÀÌµå °è¿­ÀÇ ¾à¹°ÀÌ È®´ëµÇ¸é¼­ º¸´Ù ¾ÈÀüÇϰí È¿°úÀûÀÎ ½Å°æº´Áõ Ä¡·áÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿ø°ÝÀÇ·á¿Í µðÁöÅÐ Çコ ¼Ö·ç¼ÇÀÇ ÅëÇÕÀ¸·Î ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ƯÈ÷ ÀÇ·á Á¢±Ù¼ºÀÌ Ãë¾àÇÑ Áö¿ªÀÇ ÀÇ·á Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. Áٱ⼼Æ÷ Ä¡·á¿Í À¯ÀüÀÚ ±â¹Ý °³ÀÔÀ» Æ÷ÇÔÇÑ Àç»ýÀÇ·áÀÇ ºÎ»óÀº ¿¬±¸ ÅõÀÚ¿¡ ¹ÚÂ÷¸¦ °¡ÇÏ¸ç ¹Ì·¡ Ä¡·áÀÇ °¡´É¼ºÀ» ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ »ýȰ½À°ü °³¼±°ú º¸¿Ï¿ä¹ýÀÌ °­Á¶µÇ¸é¼­ Ä¡·áÀÇ ¼±ÅÃ ÆøÀÌ ³Ð¾îÁö°í ´Ù¾çÇÑ È¯ÀÚ±º¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. Ä¡·áÁ¦, ÀÇ·á±â±â, ÀüÀÎÀû Ä¡·á Á¢±Ù¹ýÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î ´ç´¢º´¼º ½Å°æº´Áõ °ü¸® ½ÃÀåÀº ÇâÈÄ ¼ö³â°£ Áö¼ÓÀûÀÎ ¼ºÀåÀ» ÀÌ·ê ¼ö ÀÖ´Â ¿©°ÇÀÌ Á¶¼ºµÇ¾î ÀÖ½À´Ï´Ù.

ºÎ¹®

µð¹ÙÀ̽º À¯Çü(½Å°æ ÀÚ±Ø µð¹ÙÀ̽º, Àü±â ÀÚ±Ø µð¹ÙÀ̽º, ½Å°æ Àüµµ °Ë»ç µð¹ÙÀ̽º, ±âŸ µð¹ÙÀ̽º À¯Çü), ¿ëµµ(¸»ÃʽŰ溴Áõ ¿ëµµ, ÀÚÀ² ½Å°æ Àå¾Ö ¿ëµµ, ±ÙÀ§½Å°æÀå¾Ö ¿ëµµ, ´Ü½Å°æÀå¾Ö ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø ÃÖÁ¾ ¿ëµµ, ÀçÅà ÇコÄɾî ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Diabetic Neuropathy Management Market to Reach US$3.5 Billion by 2030

The global market for Diabetic Neuropathy Management estimated at US$2.7 Billion in the year 2024, is expected to reach US$3.5 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Neuro Stimulation Devices, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Electrical Stimulation Devices segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$727.9 Million While China is Forecast to Grow at 8.5% CAGR

The Diabetic Neuropathy Management market in the U.S. is estimated at US$727.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$731.5 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Diabetic Neuropathy Management Market - Key Trends & Drivers Summarized

Why Is Diabetic Neuropathy Emerging as a Major Health Concern?

Diabetic neuropathy, a severe complication of prolonged high blood sugar levels, affects millions of diabetic patients worldwide, leading to nerve damage, chronic pain, and reduced mobility. This condition primarily impacts the peripheral nervous system, causing symptoms such as tingling, burning sensations, numbness, and muscle weakness. The growing diabetic population, coupled with poor glycemic control and sedentary lifestyles, has led to an increasing incidence of diabetic neuropathy. The condition significantly impacts patients’ quality of life, making effective management strategies essential. The healthcare industry is witnessing a surge in demand for both pharmacological and non-pharmacological treatments aimed at alleviating symptoms and slowing disease progression. The increasing focus on early diagnosis and preventive measures has further propelled the need for comprehensive neuropathy management solutions, fostering market growth.

What Are the Latest Treatment Advancements in Diabetic Neuropathy Management?

The landscape of diabetic neuropathy management is evolving with the introduction of advanced therapies, including novel pharmaceuticals, neuromodulation devices, and regenerative medicine approaches. Anticonvulsants and antidepressants, such as pregabalin and duloxetine, remain the mainstay of pharmacological treatment, helping to manage neuropathic pain effectively. However, the emergence of gene therapy and nerve regeneration treatments offers promising solutions for addressing the underlying nerve damage. Non-invasive neuromodulation therapies, including transcutaneous electrical nerve stimulation (TENS) and spinal cord stimulation, are gaining traction as alternative treatments for pain relief. Additionally, stem cell therapy is being explored for its potential to restore nerve function and improve long-term outcomes. With continuous innovation in both drug and device-based therapies, the diabetic neuropathy management market is witnessing rapid expansion.

How Are Lifestyle Modifications and Alternative Therapies Shaping the Market?

Beyond conventional treatments, lifestyle modifications and alternative therapies are playing an increasingly vital role in diabetic neuropathy management. Nutritional interventions, particularly those focusing on vitamin B12 and alpha-lipoic acid supplementation, are being recommended to support nerve health and reduce oxidative stress. The growing interest in complementary therapies, such as acupuncture, herbal medicine, and physical therapy, is expanding treatment options for patients seeking holistic management approaches. Exercise programs tailored to improve nerve function and circulation are also becoming an integral part of neuropathy management. The rising preference for integrative medicine and personalized treatment plans is influencing the development of multidisciplinary care models, further enhancing patient outcomes.

What Are the Key Drivers of Growth in the Diabetic Neuropathy Management Market?

The growth in the diabetic neuropathy management market is driven by several factors, including the rising global diabetic population, increasing adoption of novel drug therapies, and advancements in neuromodulation technologies. The growing awareness of the importance of early diagnosis and intervention is prompting more patients to seek treatment, boosting market demand. The expansion of pain management solutions, particularly in non-opioid drug classes, is driving the adoption of safer and more effective neuropathy treatments. Additionally, the increasing integration of telemedicine and digital health solutions for remote patient monitoring is improving access to care, particularly in underserved regions. The rise of regenerative medicine, including stem cell therapy and gene-based interventions, is fueling research investments and expanding future treatment possibilities. Moreover, the emphasis on lifestyle modifications and complementary therapies is broadening treatment choices, catering to a diverse patient population. With continuous advancements in therapeutics, medical devices, and holistic care approaches, the diabetic neuropathy management market is poised for sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Diabetic Neuropathy Management market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Device Type (Neuro Stimulation Devices, Electrical Stimulation Devices, Nerve Conduction Testing Devices, Other Device Types); Application (Peripheral Neuropathy Application, Autonomic Neuropathy Application, Proximal Neuropathy Application, Mononeuropathy Application); End-Use (Hospitals End-Use, Home Healthcare End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â